Kalaris Therapeutics

KLRSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$55.942 M

$2.35 +16.34%

Close of 6 Nov 2026

As of 6 Nov 2026, Kalaris Therapeutics (KLRS) has a market capitalization of $55.9M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

-$43.4M

Loss-making

Shares outstanding

23,804,981

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →

#120Cognition TherapeuticsCGTX$60.2M
#121Cardiff OncologyCRDF$58.9M
#122Kalaris TherapeuticsKLRS$55.9M
#123Eloxx PharmaceuticalsELOX$52.1M
#124MiNK TherapeuticsINKT$50.7M

What if Kalaris Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$1,186,175

Per share 504,755× higher

Bitcoin $1.53T

$64,181.87

Per share 27,311× higher

Apple $5.02T

$210,703.07

Per share 89,661× higher

Or at a round number

$100.0M $200.0M $500.0M $1.00B

Where these numbers come from

Share counts and financials for Kalaris Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.